In addition to a slight and temporary risk for blood sugar imbalance, smoking cessation is associated with reduced risks for all-cause mortality and for macro- and microangiopathic complications.
EverImmune, a biotech based near Paris, and specialized in the development of live biotherapeutic products in the field of microbiota oncology, has raised €5m (US$5.7m) in a Series A funding round from undisclosed private investors.